102 related articles for article (PubMed ID: 32765870)
1. Implementation of primary HPV testing in Japan.
Kurokawa T; Yoshida Y; Iwanari O; Oishi T; Kasai T; Hamada M; Fujita H; Fujiwara H; Yokoyama M; Sakuragi N; Kigawa J; Suzuki M
Mol Clin Oncol; 2020 Oct; 13(4):22. PubMed ID: 32765870
[TBL] [Abstract][Full Text] [Related]
2. Are HPV-negative lesions concerned for the introduction of primary HPV testing for cervical cancer screening in Japan?
Hideshima M; Hashiguchi M; Honda A; Umezaki Y; Okuma R; Hikari T; Fukuda A; Okugawa K; Yokoyama M
J Obstet Gynaecol Res; 2023 Dec; 49(12):2860-2867. PubMed ID: 37667616
[TBL] [Abstract][Full Text] [Related]
3. Type-specific Distribution of Cervical hrHPV Infection and the Association with Cytological and Histological Results in a Large Population-based Cervical Cancer Screening Program: Baseline and 3-year Longitudinal Data.
Song F; Du H; Xiao A; Wang C; Huang X; Liu Z; Zhao M; Men H; Wu R
J Cancer; 2020; 11(20):6157-6167. PubMed ID: 32922555
[No Abstract] [Full Text] [Related]
4. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
5. HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile.
Lagos M; Van De Wyngard V; Poggi H; Cook P; Viviani P; Barriga MI; Pruyas M; Ferreccio C
Infect Agent Cancer; 2015; 10():43. PubMed ID: 26600869
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions.
Cuzick J; Thomas Cox J; Zhang G; Einstein MH; Stoler M; Trupin S; Behrens CM
Int J Cancer; 2013 Feb; 132(4):959-66. PubMed ID: 22806936
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Associated Factors of Abnormal Cervical Cytology and HighRisk HPV DNA among Bangkok Metropolitan Women.
Tangjitgamol S; Kantathavorn N; Kittisiam T; Chaowawanit W; Phoolcharoen N; Manusirivithaya S; Khunnarong J; Srijaipracharoen S; Saeloo S; Krongthong W; Supawattanabodee B; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(7):3147-53. PubMed ID: 27509943
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis study of HPV testing as a primary cervical cancer screening in Thailand.
Termrungruanglert W; Khemapech N; Tantitamit T; Sangrajrang S; Havanond P; Laowahutanont P
Gynecol Oncol Rep; 2017 Nov; 22():58-63. PubMed ID: 29034308
[TBL] [Abstract][Full Text] [Related]
9. HPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China.
Zheng B; Yang H; Li Z; Wei G; You J; Liang X; Zhao C
J Cancer; 2017; 8(13):2436-2441. PubMed ID: 28900480
[TBL] [Abstract][Full Text] [Related]
10. The ideal strategy for cervical cancer screening in Japan: Result from the Fukui Cervical Cancer Screening Study.
Kurokawa T; Onuma T; Shinagawa A; Chino Y; Kobayashi M; Yoshida Y
Cytopathology; 2018 Aug; 29(4):361-367. PubMed ID: 29768678
[TBL] [Abstract][Full Text] [Related]
11. HPV-based screening for cervical cancer among women 55-59 years of age.
Bergengren L; Lillsunde-Larsson G; Helenius G; Karlsson MG
PLoS One; 2019; 14(6):e0217108. PubMed ID: 31199811
[TBL] [Abstract][Full Text] [Related]
12. Cervical Cancer Screening With Human Papillomavirus DNA and Cytology in Japan.
Sasaki Y; Iwanari O; Arakawa I; Moriya T; Mikami Y; Iihara K; Konno R
Int J Gynecol Cancer; 2017 Mar; 27(3):523-529. PubMed ID: 27997455
[TBL] [Abstract][Full Text] [Related]
13. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
[TBL] [Abstract][Full Text] [Related]
14. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
[TBL] [Abstract][Full Text] [Related]
16. CADM1, MAL, and miR124 Promoter Methylation as Biomarkers of Transforming Cervical Intrapithelial Lesions.
Del Pino M; Sierra A; Marimon L; Martí Delgado C; Rodriguez-Trujillo A; Barnadas E; Saco A; Torné A; Ordi J
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31067838
[TBL] [Abstract][Full Text] [Related]
17. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
